Silence Presents Phase I Data on siRNA-based Cancer Drug at ASCO, Touts Safety of Delivery System
June 09, 2011
Silence Presents Phase I Data on siRNA-based Cancer Drug at ASCO, Touts Safety of Delivery System
The company hopes the positive safety profile of the drug will entice industry partners interested in licensing siRNA delivery systems, Silence's CEO said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ASCO Publishes Abstracts for Alnylam, Silence Cancer Drugs
May 26, 2011 / Gene Silencing News - Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
April 11, 2013 / Gene Silencing News - After Losing Another CEO, Silence Management Aims to Fill in Corporate Gaps
March 21, 2013 / Gene Silencing News - Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 2, 2012 / Gene Silencing News - Silence Says Cash Runway Ends in Q3, Directors Have 'Uncertainty' About Additional Fundraising
March 22, 2012 / Gene Silencing News